Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors

BACKGROUND: Molecularly targeted therapies using receptor inhibitors, small molecules or monoclonal antibodies are routinely applied in oncology. Verification of target expression should be mandatory prior to initiation of therapy, yet, determining the expression status is most challenging in recurr...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Transl Med
Main Authors: Schäfer, Niklas, Gielen, Gerrit H., Rauschenbach, Laurèl, Kebir, Sied, Till, Andreas, Reinartz, Roman, Simon, Matthias, Niehusmann, Pitt, Kleinschnitz, Christoph, Herrlinger, Ulrich, Pietsch, Torsten, Scheffler, Björn, Glas, Martin
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2019
Teme:
Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6425567/
https://ncbi.nlm.nih.gov/pubmed/30894200
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-019-1846-y
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki